MX2018011951A - Metodo para seleccionar proteinas recombinantes ricas en m6p. - Google Patents

Metodo para seleccionar proteinas recombinantes ricas en m6p.

Info

Publication number
MX2018011951A
MX2018011951A MX2018011951A MX2018011951A MX2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A
Authority
MX
Mexico
Prior art keywords
recombinant human
selection
human lysosomal
recombinant proteins
lysosomal proteins
Prior art date
Application number
MX2018011951A
Other languages
English (en)
Inventor
Gotschall Russell
V Do Hung
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018011951A publication Critical patent/MX2018011951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Métodos para producir, capturar y purificar proteínas lisosomales humanas recombinantes. Estas proteínas lisosomales humanas recombinantes pueden tener un contenido elevado de residuos de manosa-6-fosfato. Composiciones farmacéuticas que comprenden estas proteínas lisosomales humanas recombinantes. Métodos de tratamiento. Usos de estas proteínas lisosomales humanas recombinantes.
MX2018011951A 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p. MX2018011951A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins
PCT/US2017/024981 WO2017173059A1 (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Publications (1)

Publication Number Publication Date
MX2018011951A true MX2018011951A (es) 2019-02-13

Family

ID=58640993

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011951A MX2018011951A (es) 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Country Status (13)

Country Link
US (3) US10227577B2 (es)
JP (3) JP7046003B2 (es)
KR (3) KR102343162B1 (es)
AU (2) AU2017239640B2 (es)
BR (1) BR112018070189A2 (es)
CA (1) CA3019354A1 (es)
CL (1) CL2018002767A1 (es)
IL (2) IL295551A (es)
MX (3) MX2018011951A (es)
PE (1) PE20190127A1 (es)
SG (1) SG11201808592PA (es)
WO (1) WO2017173059A1 (es)
ZA (2) ZA201807184B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019128A1 (en) * 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL295551A (en) * 2016-03-30 2022-10-01 Amicus Therapeutics Inc A method for selecting recombinant proteins with a high amount of mannose-6-phosphate
EP3568152A1 (en) * 2017-01-10 2019-11-20 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
HUE062504T2 (hu) * 2017-05-15 2023-11-28 Amicus Therapeutics Inc Rekombináns humán savas alfa-glükozidáz
JP2022546587A (ja) * 2019-09-06 2022-11-04 アミカス セラピューティックス インコーポレイテッド 生物製剤の捕捉及び精製のための方法
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202400212A (zh) * 2022-05-05 2024-01-01 美商阿米庫斯醫療股份有限公司 用於治療龐貝氏病之方法
WO2024119091A1 (en) 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients
WO2024119070A1 (en) 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000034451A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
AU6050600A (en) 1999-07-26 2001-02-13 G.D. Searle & Co. Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK3108895T3 (en) 2000-07-18 2018-11-26 Univ Duke Treatment of glycogen storage disease type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
WO2003032907A2 (en) 2001-10-16 2003-04-24 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
WO2008063511A2 (en) 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US20100317690A1 (en) 2007-11-21 2010-12-16 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP2260107A4 (en) 2008-03-12 2011-03-23 Amicus Therapeutics Inc TESTS FOR THE DIAGNOSIS AND ASSESSMENT OF TREATMENT OPTIONS FOR MORBUS POMPE
EP2252325A4 (en) 2008-03-12 2012-07-11 Amicus Therapeutics Inc TREATMENT OF MORBUS POMPE WITH SPECIFIC PHARMACOLOGICAL CHAPTERONES AND TREATMENT MONITORING WITH SURROGATE MARKERS
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
US8835614B2 (en) 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP2483399B1 (en) * 2009-09-29 2019-03-27 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2812870C (en) 2010-09-29 2020-06-09 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
PE20140617A1 (es) 2011-04-22 2014-05-28 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CA2860085A1 (en) 2011-12-22 2013-06-27 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
RS61598B1 (sr) 2012-05-03 2021-04-29 Amicus Therapeutics Inc Režimi doziranja za tretman pompeove bolesti
WO2013182652A1 (en) 2012-06-06 2013-12-12 Fondazione Telethon Allosteric chaperones and uses thereof
CN107075468B (zh) * 2014-09-30 2021-12-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
IL295551A (en) * 2016-03-30 2022-10-01 Amicus Therapeutics Inc A method for selecting recombinant proteins with a high amount of mannose-6-phosphate

Also Published As

Publication number Publication date
US20230079225A1 (en) 2023-03-16
IL262060B (en) 2022-09-01
JP2024063015A (ja) 2024-05-10
ZA201807184B (en) 2021-02-24
US20190382742A1 (en) 2019-12-19
KR20210157477A (ko) 2021-12-28
JP2019509754A (ja) 2019-04-11
CA3019354A1 (en) 2017-10-05
IL295551A (en) 2022-10-01
MX2022014532A (es) 2022-12-13
KR102455821B1 (ko) 2022-10-18
WO2017173059A1 (en) 2017-10-05
IL262060A (en) 2018-11-29
JP7436545B2 (ja) 2024-02-21
KR102343162B1 (ko) 2021-12-23
JP2022101545A (ja) 2022-07-06
AU2017239640A1 (en) 2018-10-25
US10227577B2 (en) 2019-03-12
KR20180128945A (ko) 2018-12-04
KR20220145918A (ko) 2022-10-31
US20170335301A1 (en) 2017-11-23
JP7046003B2 (ja) 2022-04-01
CL2018002767A1 (es) 2019-01-11
PE20190127A1 (es) 2019-01-17
MX2022014533A (es) 2022-12-13
SG11201808592PA (en) 2018-10-30
US11441138B2 (en) 2022-09-13
AU2017239640B2 (en) 2022-07-28
BR112018070189A2 (pt) 2019-02-19
ZA202006604B (en) 2023-04-26
AU2022259797A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2022014532A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MX2017010673A (es) Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MY187486A (en) Cysteine protease
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2018011162A (es) Metodos de purificacion de colageno 7.
WO2015161243A3 (en) Beta-lactamases with improved properties for therapy
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
NZ728401A (en) High purity oritavancin and method of producing same
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2019013458A (es) Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
PH12020551618A1 (en) Erenumab compositions and uses thereof